glp-1 food trends news Use and Its Impact on Choices and Retail Behavior GLP-1 weight loss drug boom

Type 2 diabetes is a chronic condition that occurs when the body does not use insulin well and cannot keep blood sugar at normal levels

Outcomes suggest semaglutide produced poorer outcomes, with a significantly elevated incidence of all-cause mortality (Risk Ratio [RR]: 1.56), AMI (RR: 1.21), ischemic stroke (RR: 1.64, p=0.024) and readmission (RR: 1.15) compared to tirzepatide

HM15275 and HM17321, both scheduled for presentation at ADA 2025, represent next-generation pipelines following the innovation of efpeglenatide, which is targeted for commercialization in the second half of 2026

Results and experiences may vary

Gwyneth Paltrow, Andrew Huberman, and Retatrutide: What the New GLP-1 Conversation Means for Muscle-Preserving Weight Loss Retatrutide is quickly becoming one of the most talked-about names in weight-loss medicine